D http://www.metronidazole500mg.com/faq ., Ph.D., Miguel A.D.D., Ph.D., Amparo Ruiz, M.D., Manuel Ramos, M.D., Encarna Adrover, M.D., Ignacio Aranda, M.D.D., Ph.D.D., Lourdes Calvo, M.D.D., Ph.D., Dolores Isla, M.D., Ph.D.D., Manuel Ruiz Borrego, M.D., Jerzy Zaluski, M.D., Angels Arcusa, M.D.D.D., Ph.D. Mel, M.D., Ph.D., Blanca Munarriz, M.D., Ph.D., Cristina Llorca, M.D., Ph.D., Carlos Jara, M.D., Ph.D., Emilio Alba, M.D., Ph.D.D., Junfang Li, Ph.D.D.D.D., Sergio Almenar, M.D.D., and Ana Lluch, M.D., Ph.D. For the GEICAM 9805 Investigators: Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer The survival benefits of adjuvant chemotherapy for patients with early-stage breast cancer are well established.
King Pharmaceuticals supplied financial support and donated antihypertensive medications to each clinical middle. Pfizer, AstraZeneca, GlaxoSmithKline, Forest Laboratories, Pharmacia, and Upjohn also donated antihypertensive medications. None of these ongoing businesses had any part in the design of the study, the accrual or evaluation of data, or the preparation of the manuscript.18 The consequences of blood-pressure targets on trial outcomes had been evaluated with the use of Cox proportional-hazards regression with adjustment for five prespecified baseline factors and randomized drug assignment. An conversation term of follow-up time with the log-transformed baseline protein-to-creatinine ratio was included as a covariate to take into account a transformation in the hazard ratio for baseline urinary proteins excretion as time passes.